Compare NUVL & IDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | IDA |
|---|---|---|
| Founded | 2017 | 1915 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.9B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | IDA |
|---|---|---|
| Price | $100.82 | $144.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $135.00 | ★ $135.25 |
| AVG Volume (30 Days) | 497.6K | ★ 500.1K |
| Earning Date | 02-27-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | N/A | ★ 7.17 |
| EPS | N/A | ★ 5.84 |
| Revenue | N/A | ★ $1,805,885,000.00 |
| Revenue This Year | N/A | $7.90 |
| Revenue Next Year | N/A | $8.27 |
| P/E Ratio | ★ N/A | $24.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $108.15 |
| 52 Week High | $113.02 | $142.06 |
| Indicator | NUVL | IDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 77.24 |
| Support Level | $98.65 | $134.31 |
| Resistance Level | $106.57 | $137.28 |
| Average True Range (ATR) | 4.46 | 2.51 |
| MACD | -0.29 | 0.77 |
| Stochastic Oscillator | 47.36 | 94.40 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.